# SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma

> **NCT00867750** · PHASE2 · COMPLETED · sponsor: **Sirtex Medical** · enrollment: 28 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** Radioembolisation (SIR-Spheres® microspheres)
- **DRUG:** Transarterial Chemoembolisation

## Key facts

- **NCT ID:** NCT00867750
- **Lead sponsor:** Sirtex Medical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00867750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00867750, "SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00867750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*